Early Cardiovascular Events in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation
Authors' conclusion
Although CV events are relatively uncommon in the first 100 days in patients after allogeneic HSCT, the occurrence of CV events is associated with high nonrelapse and all-cause mortality rates. Close monitoring of patients who develop CV events is recommended.
Study context
- Population
- Adult patients who underwent allogeneic hematopoietic stem cell transplantation (HSCT) between 2004 and 2022median age: 54 years, 58.57% male
- Participants
- 852 patients
- Outcome
- CV events:
- CV death
- Myocardial infarction
- Heart failure
- Arrhythmia
- Stroke
- Transient ischemic attack
- Follow-up
- 100 days
Main finding
As reported in the abstract
100-day cumulative incidence of cardiovascular (CV) events
5.55%
95% CI 4.13%–7.26%
Observational data: associations, not effects.
Further findings
Risk factors for CV events
| Estimate | ||
|---|---|---|
| AgeIndependently associated with increased risk | SHR per year 1.07 (95% CI 1.03–1.13) | |
| Left ventricular ejection fraction <50% before transplantIndependently associated with increased risk | SHR 3.16 (95% CI 1.43–6.98) | |
| 0.10.31310Ratio (log scale) |
Nonrelapse mortality and all-cause mortality with nonfatal CV events · first 100 days
| Estimate | ||
|---|---|---|
| Nonfatal CV eventsNonrelapse mortality · independently associated | SHR 6.25 (95% CI 2.83–13.79) | |
| Nonfatal CV eventsAll-cause mortality · independently associated | HR 5.79 (95% CI 2.87–11.68) | |
| 0.050.21520Ratio (log scale) |
Atrial arrhythmia · 100 days
- Cumulative incidence (most frequent cardiac event)
- 3.92% [95% CI: 2.84%-5.56%]
Heart failure · 100 days
- Cumulative incidence
- 2.07% [95% CI: 1.26%-3.24%]
Original publication
Early Cardiovascular Events in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation. JACC Adv. Published 22 May 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →